# Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

> **NCT02281760** · PHASE2 · COMPLETED · sponsor: **National Human Genome Research Institute (NHGRI)** · enrollment: 9 (actual)

## Conditions studied

- BRAF V600E Mutation

## Interventions

- **DRUG:** Dabrafenib Mesylate
- **DRUG:** Trametinib Dimethyl Sulfoxide

## Key facts

- **NCT ID:** NCT02281760
- **Lead sponsor:** National Human Genome Research Institute (NHGRI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-01
- **Primary completion:** 2018-08-29
- **Final completion:** 2018-08-29
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02281760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02281760, "Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02281760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*